They hypothesized that XO inhibitors could mitigate vulnerability to hypertension-related AF by improving the intracellular ROS environment and inhibiting the ox-Ca2+-calmodulin-dependent protein-kinase type-II (CaMKII) signaling pathway, which regulates heart contraction [44,45]. Here, CAMK2G is linked to hypertensive disorder.